TNNI3 Human Chimeric

Cardiac Troponin-I Chimeric Human Recombinant
Cat. No.
BT17168
Source
Escherichia Coli.
Synonyms

Troponin I cardiac muscle, Cardiac troponin I, TNNI3, TNNC1, CMH7, RCM1, cTnI, CMD2A, MGC116817.

Appearance

Sterile Filtered White lyophilized (freeze-dried) powder.

Purity

Greater than 95.0% as determined by SDS-PAGE.

Usage
Prospec's products are furnished for LABORATORY RESEARCH USE ONLY. The product may not be used as drugs, agricultural or pesticidal products, food additives or household chemicals.
Shipped with Ice Packs
In Stock

Description

TNNI3 Human Chimeric produced in E.Coli is a single, non-glycosylated polypeptide chain (28-110 a.a.) and having a molecular mass of 29072 Dalton.  

Product Specs

Description
TNNI3 Human Chimeric produced in E.Coli is a single, non-glycosylated polypeptide chain (28-110 a.a.) and having a molecular mass of 29072 Dalton.
Physical Appearance
Sterile Filtered White lyophilized (freeze-dried) powder.
Formulation
TNNI3 was lyophilized in 50mM Tris-HCl, 5mM Calcium chloride, 0.7M KCl and 0.1% 2-mercaptoethanol, pH 7.5
Stability
Lyophilized Cardiac Troponin-I Chimeric although stable at room temperature for 3 weeks, should be stored desiccated below -18°C. Upon reconstitution TNNI3 should be stored at 4°C between 2-7 days and for future use below -18°C. For long term storage it is recommended to add a carrier protein (0.1% HSA or BSA). Please prevent freeze-thaw cycles.
Solubility
It is recommended to reconstitute the lyophilized TNNI3 in buffer containing BSA not less than 100µg/ml, which can then be further diluted to other aqueous solutions.
Purity
Greater than 95.0% as determined by SDS-PAGE.
Synonyms

Troponin I cardiac muscle, Cardiac troponin I, TNNI3, TNNC1, CMH7, RCM1, cTnI, CMD2A, MGC116817.

Source
Escherichia Coli.

Product Science Overview

Introduction

Cardiac Troponin-I (cTnI) is a critical component of the troponin complex, which plays a pivotal role in the regulation of cardiac muscle contraction. The troponin complex consists of three subunits: Troponin I (cTnI), Troponin T (cTnT), and Troponin C (cTnC). Among these, cTnI is unique to cardiac muscle and serves as a highly specific biomarker for myocardial injury, particularly in the diagnosis of acute myocardial infarction (AMI) .

Development of Human Recombinant cTnI

The development of human recombinant cTnI involves the use of recombinant DNA technology to produce a synthetic version of the protein. This process typically includes the following steps:

  1. Gene Cloning: The gene encoding human cTnI is isolated and inserted into a suitable expression vector.
  2. Transformation: The vector is introduced into a host cell, often Escherichia coli or yeast, which will express the recombinant protein.
  3. Protein Expression: The host cells are cultured under conditions that promote the expression of cTnI.
  4. Purification: The recombinant cTnI is extracted and purified using techniques such as affinity chromatography.

The resulting human recombinant cTnI is used in various clinical assays to measure troponin levels in patients’ blood samples, aiding in the diagnosis and management of cardiac conditions .

Significance in Clinical Diagnostics

Human recombinant cTnI is crucial for standardizing clinical assays, ensuring consistency and accuracy across different laboratories and testing platforms. The use of recombinant cTnI helps mitigate the variability observed in traditional assays, which can differ significantly in their sensitivity and specificity .

Quick Inquiry

Personal Email Detected
Please use an institutional or corporate email address for inquiries. Personal email accounts ( such as Gmail, Yahoo, and Outlook) are not accepted. *
© Copyright 2024 Thebiotek. All Rights Reserved.